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Abstract
Background: The incidence of migraine has been investigated only in a few studies worldwide and it is not
known in our country. We, therefore, aimed to estimate the migraine incidence in a previously accomplished
population-based prevalence study sample of 5323 individuals in the year 2008.
Methods: The former Turkish headache prevalence study has been completed as a nationwide, randomized,
home-based study of face-to-face examination by physicians trained for headache diagnosis by using ICHD
criteria. Five years after this study an optimized survey including 50 questions was performed to estimate the
migraine incidence in migraine-free individuals in the previous study, with a 56.4 % responder rate. Two validation
studies for this survey were performed prior and after the study each in 100 subjects by comparing the gold standard
of expert diagnosis of headache, showing high rate of reliability (Crohnbach alpha: 0.911 and 0.706, respectively).
Results: Migraine incidence was estimated as 2.38 % (2.98 % in women and 1.93 % in men) per year in 2563
migraine-free individuals; if the population at risk is defined as the group without any headaches, the migraine incidence
decreased to 1.99 %. The chronic migraine (CM) incidence [without medication overuse (MOH)] was 0.066 % and that of
MOH was 0.259 %. We found a significant burden of the disease on the occupational functionality as well as
on social and family life, even in the early years of the migraine. The family history of headaches especially in
the fathers could be useful to predict new cases of migraine, besides the well-known risk factor, diagnosis of
depression, whereas income and education did not seem to relate to migraine onset.
Conclusions: Our study with a large population-based nation-wide sample, using ICHD-II criteria, with structured
headache interviews as well as blinded re-validation of the questionnaire diagnoses showed a 2.38 % incidence rate of
migraine in Turkey, higher than most of the other previous reports; a finding which could be related to genetic factors
and also to the methodological differences in the study designs. Moreover the incidence of CM was found to
be 0.066 %.
Keywords: Migraine, Incidence, Headache epidemiology
* Correspondence: betulbaykanbaykal@gmail.com; esmeekizoglu@yahoo.com
†Equal contributors
1Department of Neurology, Istanbul Faculty of Medicine, Istanbul University,
Millet Cad, 34390 Capa/Istanbul, Turkey
Full list of author information is available at the end of the article
© 2015 Baykan et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Baykan et al. The Journal of Headache and Pain  (2015) 16:103 
DOI 10.1186/s10194-015-0589-2
Background
Headache was highlighted as the third cause of disability
worldwide and migraine is a frequent form of headache
disorders causing remarkable disability during the head-
ache attacks along with substantial social and financial
burden to the patient as well as to the society [1, 2]. The
prevalence of migraine for Western countries is estab-
lished as nearly between 5 and 9 % for men and between
12 and 25 % for women [3, 4]. These figures are subject
to change between countries and races; reported rates of
migraine are lower in Asia and Africa than in Western
countries. Prevalence studies have already demonstrated
the magnitude of health impact caused by migraine but
incidence studies needing further huge efforts may con-
tribute to our understanding of migraine mechanisms
towards the identification of important risk factors. The
introduction of the International Classification of Head-
ache Disorders (ICHD) have stimulated valuable preva-
lence studies of population-based data, however, there is
only one population-based incidence study done in
Germany with new ICHD-II edition so far [3–7].
There are still many methodological problems with
respect to epidemiological studies about the migraine
[3–7]. Unfortunately, migraine incidence studies are
surprisingly scant due to its challenging aspects; as a
result relatively little is known about its incidence.
Besides being uncommon many of the migraine inci-
dence studies carry some methodological concerns or
confined to selected age groups such as children and
adolescents [8–12].
Furthermore the estimated migraine incidence figures
from these studies are quite variable. This variability
may depend on methodological differences, on case defi-
nitions and study characteristics; many of the previous
studies based on small samples of relatively few new-
onset cases [3, 7]. Moreover Stewart et al. showed in a
cross-sectional survey study with a large sample and broad
age range that the cumulative lifetime risk of migraine is
2.5–3 times higher than prevalence, intriguingly [13].
We previously published a nation-wide population-
based prevalence study in our country bridging Asia and
Europe and the gold-standard of headache diagnosis
established by face to face personal interview and exam-
ination by physicians were applied in this first study
[14]. Our current aim is to estimate the migraine inci-
dence in this previously well-investigated population
sample, for the first time in Turkey. Our secondary aim
was to assess the associated risk factors for migraine
development in these series.
Methods
Two steps of the incidence study
1) The first step of this study, namely Turkish headache
prevalence study was completed in 2008 on 5323
households aged between 18 to 65 years. This former
study was designed as a nationwide, randomized, home-
based study of face-to-face examination by general prac-
titioners specifically educated for headache diagnosis by
using ICHD-II criteria and published in 2012 [14]. In
2013, five years after this prevalence study, a second
study was planned to be done with the same subjects of
the first study. We aimed to contact all individuals who
were migraine-free in 2008 to calculate the incidence of
migraine in the general Turkish population.
2) The second part of study was designed in 2 sessions
by headache experts as a telephone survey of all in-
cluded subjects of the first study. For this telephone sur-
vey, a new questionnaire with 50 questions consisting of
both diagnostic and investigational points was prepared.
The survey was first optimized for convenient use of
time and intelligibility of the questionnaire after first 10
telephone interviews. Trained call center employees did
the telephone calls, asked the questions of the question-
naire and recorded the answers first by re-taking the
consent of the called subject after reminding his/her first
contribution to the study 5 years ago. For the validation
of current telephone survey, two different validation
studies were performed in two phases; first one was the
“pre-study validation” and second one was the “post-
study validation”. Ethical committee approved the study
protocol.
Pre-study validation
In the beginning of the study, 100 subjects living in two
cities were randomly selected among 5323 subjects of
the first study. First the call center employees had called
them and implemented the questionnaire as planned.
Then, the same subjects were invited to the headache
centers of the university hospitals (in the metropolis of
Istanbul and Bursa) for a face-to-face interview by the
headache experts to establish the gold standard of “clin-
ical headache diagnosis”. Of 100 subjects, 49 have ac-
cepted the invitation and received headache diagnoses
by experts. The interobserver reliability analysis of
headache diagnoses between the telephone interview
and the headache specialist examination revealed that
the questionnaire was excellently reliable (Crohnbach
alpha: 0.911).
Telephone survey
Fifty-item questionnaire intended to be implemented in
a total of 5323 households could be administered in
3001 subjects, with a 56.4 % responder rate. Of 3001
subjects, 2563 [currently aged between 23 and 71 years
(mean ± standard deviation; 41.7 ± 12)] were migraine-
free at the time of the first prevalence study in the year
of 2008 and they were used in the calculation of mi-
graine incidence for the purpose of the current study.
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Post-study validation
In the end of the telephone survey study, another ran-
domly selected sample of 100 subjects living in the same
cities were invited to the university hospitals for a face
to face interview with the headache specialists to make a
clinical headache diagnosis. Of 100 subjects, 73 accepted
to come to the visit. The reliability analysis of headache
diagnoses between questionnaire by telephone call and
the headache diagnoses by the headache specialist re-
vealed that the questionnaire was again strongly reliable
(Crohnbach alpha: 0.706).
Secondary aims
Risk factors for migraine development were calculated
based on the status of migraine-free individuals in 2008,
comparing the subgroups with and without definite mi-
graine in 2013. Incidence of chronic migraine (CM) and
medication overuse headache (MOH) was also estimated
in the study population excluding only patients with CM
or MOH diagnosis in 2008. The impact of migraine on
the patients’ life and their headache burden were also in-
vestigated based on questionnaire. Furthermore, medical
consultation for headache of the patients in 2008 and of
those in 2013 (without any headache in 2008) has been
explored.
Statistical analysis
SPSS 15.0 program was used for statistical analysis.
Descriptive statistics were applied for the relevant pa-
rameters. Reliability analysis (Crohnbach alpha) was done
between the telephone survey and expert diagnosis, before
and after the survey. Chi-square test and t test were used
for the group comparisons, where appropriate.
Results
Migraine incidence is estimated as 2.38 % per year, from
314 new incident cases in 2563 subjects (the migraine-
free individuals in the year 2008 defined as subjects who
were not diagnosed as definite migraine according to
ICHD criteria) in the following 5.15 years. The incidence
is 2.98 % per year in women and 1.93 % per year in men.
Figure 1 shows the annual incidence rates in age groups,
both for women and men. If the population at risk is
defined as the group without any headaches in the
year 2008 [1839 participants without any headache
(747 females, 1092 males)], the calculated migraine
incidence falls to 1.99 % (2.44 % females, 1.67 % males),
whereas headache incidence is 8.67 % per year
(9.91 % females, 7.83 % males) (Table 1).
The new migraine prevalence, which was 16.4 % in
this cohort in 2008, is estimated as 16.7 % in 3001 per-
sons, aged between 23 and 70 years, who answered the
questionnaire in 2013.
Moreover, CM incidence (without medication overuse)
was 0.066 %; and the incidence of MOH was 0.259 % in
2928 subjects excluding only CM or MOH (73 patients),
and including episodic migraineurs in the year 2008.
Among the 314 new incident cases with definite mi-
graine, the rate of CM was 0.56 % (0.8 % in males and
0.35 % in females) and that of MOH was 1.05 %. Tables 2
and 3 summarizes data of CM and MOH in Turkish
population. The most overused analgesic drugs are
nonsteroidal analgesic drugs (65.6 %) followed by sim-
ple analgesics (34.4 %), ergotamins (18.8 %) and trip-
tans (15.6 %) in new incident 32 patients. Headache
characteristics and burden of patients with new inci-
dent migraine were given in the Table 4.
We also compared some possible baseline predictive
factors like education, income status, diagnosis of de-
pression and family history of migraine between new
incident cases of definite migraine and migraine-free
individuals in the years 2008 through 2013 (Table 5).
Moreover, the consulted physicians’ specialty in the
years 2008 and 2013 were both shown in the Fig. 2.
Fig. 1 The annual incidence rates in age groups
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Discussion
Our migraine incidence study complements the previous
nationwide prevalence study and showed that migraine
incidence is 2.38 % (2.98 % for women and 1.93 % for
men) per year in Turkey in the last 5 years. Moreover,
the incidence of CM and MOH were investigated in CM
and MOH-free subjects and found to be 0.066 and
0.259 %, respectively. Our results also showed the sig-
nificant burden of migraine on the occupational func-
tionality as well as on social and family life, even in the
early years of the migraine. We also noted that the
history of headaches in the fathers could be useful to
predict new cases of migraine, besides the well-known
risk factor, diagnosis of depression.
Comparison of our findings with other incidence studies
Due to the challenging aspects, only a handful of previ-
ous studies have been published on the incidence of mi-
graine so far. Some retrospective reports [15, 16] have
estimated the incidence of migraine from recalled age at
onset in cross-sectional studies with telephone inter-
views only and therefore have limitations related to this
retrospective design, like recall bias. The retrospective
studies and another study [17] which investigated med-
ical record system, reported incidence rates about 1.5–2
per 1000 person-years for men, and about 3–6 per 1000
person-years for women, all seem rather low in compari-
son to our data. The migraine incidence rate was found
as 3.69 cases per 1000 person-years, in a study based on
Table 1 Migraine incidence and prevalence estimates in different age groups
Migraine incidence Migraine prevalence OR (95 % CI)
(excluding old migraineurs) (including old migraineurs)
per year (%) n = 2563 (%) n = 3001
Women Men Total Women Men Total
Age groups (years) 18–24 2.49 1.13 1.85 15.7 8.3 12.4 0.487 (0.177–1.340)
25–29 3.03 1.91 2.38 20.9 10.4 15.3 0.436 (0.251–0.760)
30–34 4.12 2.02 2.90 26.6 12.5 18.7 0.392 (0.258–0.618)
35–39 3.35 2.10 2.61 22.6 15.2 18.4 0.612 (0.370–1.012)
40–44 3.70 2.81 3.14 25.5 16.7 20.7 0.585 (0.345–0.991)
45–49 2.68 2.07 2.35 25.5 15.5 20.7 0.535 (0.316–0.907)
50–54 2.87 1.67 2.24 20.0 9.3 14.7 0.409 (0.203–0.825)
55–59 1.60 1.40 1.49 16.8 10.7 13.7 0.596 (0.279–1.270)
60–65 1.83 0.90 1.26 13.8 6.7 9.7 0.444 (0.150–1.318)
65+ 1.17 2.06 1.67 10.0 10.6 10.3 1.068 (0.338–3.376)
18–70 2.98 1.93 2.38 21.6 12.4 16.7 0.512 (0.421–0.623)
Table 2 Chronic migraine (CM) incidence and prevalence values*
Age groups
(years)
CM incidence CM prevalence OR (95 % CI)
(%) n = 2928 (%) n = 502
Women Men Total Women Men Total
18–24 0.000 0.000 0.000 0.0 0.0 0.0
25–29 0.000 0.000 0.000 0.0 4.3 1.6 1.045 (0.958–1.141)
30–34 0.085 0.000 0.038 1.6 1.0 1.0 0.984 (0.952–1.016)
35–39 0.114 0.000 0.049 2.5 0.0 1.3 0.975 (0.928–1.025)
40–44 0.131 0.106 0.117 2.5 6.5 4.2 2.690 (0.233–31.109)
45–49 0.222 0.114 0.169 4.3 7.4 5.4 1.800 (0.239–13.569)
50–54 0.140 0.0000 0.070 3.4 0.0 2.4 0.966 (0.901–1.034)
55–59 0.000 0.971 0.085 0.0 7.7 3.1 1.083 (0.926–1.267)
60–65 0.000 0.000 0.000 0.0 0.0 0.0
65+ 0.329 0.000 0.157 16.7 14.3 15.4 0.833 (0.041–16.994)
*CM (without medication overuse) incidence values among the population without CM or medication overuse headache (MOH) diagnosis in 2008 (including old
episodic migraineurs) and CM prevalence values in patients with definite migraine (including old migraineurs) in 2013 study
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Table 3 Medication overuse headache (MOH) incidence and prevalence values*
Age groups
(years)
MOH incidence MOH prevalence OR (95 % CI)
(%) n = 2928 (%) n = 502
Women Men Total Women Men Total
18–24 0.452 0.000 0.246 14.3 0.0 10.0 0.857 (0.692–1.062)
25–29 0.313 0.177 0.239 5.0 4.3 4.8 0.864 (0.074–10.081)
30–34 0.511 0.000 0.227 6.6 0.0 4.1 0.934 (0.874–0.999)
35–39 0.454 0.260 0.344 5.0 8.6 6.7 1.781 (0.280–11.328)
40–44 0.656 0.106 0.352 10.0 6.5 8.5 0.621 (0.106–3.631)
45–49 0.111 0.114 0.113 4.3 3.7 4.1 0.865 (0.075–10.014)
50–54 0.279 0.142 0.211 6.9 7.7 7.1 1.125 (0.093–13.636)
55–59 0.890 0.162 0.509 26.3 0.0 15.6 0.737 (0.563–0.064)
60–65 0.000 0.000 0.000 0.0 0.0 0.0
65+ 0.000 0.597 0.313 0.0 14.3 7.7 1.167 (0.862–1.579)
*MOH incidence values among the population without chronic migraine (CM) or MOH diagnosis in 2008 (including old episodic migraineurs) and MOH prevalence
values in patients with definite migraine (including old migraineurs) in 2013 study
Table 4 Headache characteristics and burden of patients with new incident migraine
Women Men Total
n = 168 n = 146 n = 314
Headache frequency per month mean (± SD) 5.5 ± 5 5.2 ± 5 5.3 ± 5
Headache days per month mean (± SD) 5.9 ± 5 5.4 ± 6 5.7 ± 6
Headache duration (hours) without medication mean (± SD) 27.0 ± 95 20.9 ± 84 24.2 ± 90
Headache severity (0–3 scale) mean (± SD) 2.06 ± 0.7 2.03 ± 0.6 2.05 ± 0.6
Self Assessment of Poor Quality of Life (%)
Usually 34 32 33
Sometimes 45 47 46
Never 21 21 21
Economic loss due to migraine (%)
Usually 20 15 18
Sometimes 33 38 35
Never 47 47 47
Poor relations with family (%)
Usually 32 22 28
Sometimes 35 40 37
Never 33 38 35
Poor relations with friends (%)
Usually 32 24 28
Sometimes 31 36 33
Never 37 40 39
Loss of work time (workers) (%) (n = 65) (n = 119) (n = 184)
Yes 34 27 29
No 66 73 71
Loss of school time (students) (%) (n = 12) (n = 8) (n = 20)
Yes 42 50 45
No 58 50 55
SD Standard deviation
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the general practitioners’ records in UK [18]. On the
other hand Breslau et al. estimated the incidence of
migraine per 1,000 person-years as 5.0 for males and
22.0 for females in United States, in a follow-up study
of adults aged 21–30 years from a large health main-
tenance organization; where they also aimed to assess
the bidirectional influences between major depression
and migraine. Their study group was smaller than
ours and therefore they likely underestimated the in-
cidence of migraine because they included subjects
from a very narrow age range [19, 20]. Swartz et al.
did not really assess migraine at baseline but screened
the population at-risk and found similar figures [21].
Moreover in US, migraine incidence data was estimated
using reconstructed cohort methods [13], the incidence
(1.8 %) peaked in women aged 20 to 24 years, whereas
they found the peak in 15- to 19-year-old men (0.6 %). An
important population-based Danish study [9] found a rate
of 0.8 % per year (male:female ratio, 1:6; among 740 indi-
viduals examined in 1989, 673 were eligible in 2001 and
549 participated only; of the 453 subjects ranging in age
from 25 to 64 years who did not have migraine in 1989,
42 developed migraine during the study period) in the
general population of a single city (Copenhagen) following
a previous study after 12 years. They used ICHD criteria
and the interviews were done by a physician, either by
personal examination or by telephone interviews. Their
initial modest-sized cohort was restricted to adults aged
25–64 years, thus restricting them to estimate incidence
rates in younger age groups and the annual incidence in
females was 1.5 % and in males 0.3 %. They reported that
migraine incidence rates declined with age, was highest in
the 25 to 34 years of age group in both women and men
and was lowest for both genders in the 55 to 64 years of
age group; somewhat similar to our findings, except that
we found the highest rate in 40–44 age group in men.
Thus the differences in study populations (e.g. age, geo-
graphical area) may as well have an effect on the re-
ported differences, besides methodological aspects.
Our study investigated a larger population sample
after 5 years in 21 cities of Turkey with ICHD-II and
our incidence figure of 2.38 % is higher than most of
the other previous reports, which used ICHD-I. Also
the migraine prevalence rates in Turkey have been in-
vestigated 3 times [in 1998, 2007 and 2008 [14, 22, 23]]
and now in 2012 were more or less the same (between
16.4 and 16.7 %) which were again higher than most of
the reported prevalence rates, supporting this high mi-
graine incidence in our country. Genetic factors may
contribute to these higher prevalence and incidence
Table 5 The comparison of some baseline risk factors between new incident cases of definite migraine and migraine-free
individuals*
Assessed factor New-onset migraineurs Migraine-free individuals P Odd Ratio (95 % CI)
(n:314) (n: 2249)
Monthly income
more than 1300USD 95 (30.3 %) 621 (27.6 %) NS 1.137 (0.878–1.471)
less than 1300USD 219 (69.7 %) 1628 (72.3 %)
Diagnosis and treatment for depression** 0.010
yes 58 (18.8 %) 296 (13.4 %) 1.503 (1.102–2.051)
no 250 (81.2 %) 1918 (86.6 %)
Headache in family
yes 172 (54.8 %) 1069 (47.5 %) 0.016 1.337 (1.055–1.695)
no 142 (45.2 %) 1180 (52.5 %)
Mother with headache
yes 93 (29.6 %) 631 (28.1 %) NS 1.079 (0.833–1.398)
no 221 (70.4 %) 1618 (71.9 %)
Father with headache
yes 54 (17.2 %) 243 (10.8 %) 0.001 1.715 (1.243–2.366)
no 260 (82.8 %) 2006 (89.2 %)
Education
more than 8 years 228 (72.6 %) 1598 (71.1 %) NS 1.080 (0.829–1.407)
8 years or less 86 (27.4 %) 651 (28.9 %)
*these comparison groups included only migraine-free individuals in the baseline (year 2008). ** Six migraineurs and 35 migraine-free individuals do not
remember any history of depression
Ns:not significant with Pearson’s chi-square test (two-sided)
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rates in Turkey, but it is possible that these high rates
may as well relate to study methodology.
Furthermore, a recent carefully designed German
study using ICHD-II has drawn attention to the defin-
ition of “people at risk for migraine” and suggested that
different definitions of the population at risk limits the
comparability of the reported incidence estimates among
the published prospective studies on the migraine inci-
dence. They found that the incidence of migraine ranged
between 0 and 3.3 % in three groups of participants a)
without any headache b) without definite and probable
migraine and c) without definite migraine, probable mi-
graine and definite TTH at baseline [5]. In our study, if
the population at risk was defined as the group without
any headaches in the year 2008, the calculated migraine
incidence declines to 1.99 %.
Epidemiology of chronic migraine
CM has been a debatable definition in headache classifi-
cation and was therefore mostly neglected in epidemio-
logical studies or grouped as chronic daily headache
(CDH) with or without MOH [1]. The average cross-
study estimate of the prevalence of CM was 0.5 % with a
range from 0.2 to 2.7 % with a possible bias from the ap-
plication of different diagnostic criteria and definitions
across studies [7, 24–26]. When patients with MOH
were included, then the estimated global prevalence of
CM ranged between 1 and 5 % [27–31].
In an interesting study, Bigal et al. showed that about
2.5 % of patients with episodic migraine progressed to
CM over a one year period [32] by using Silberstein-
Lipton criteria [33] treating MOH as a subset of patients
within the CM group. We estimated the CM incidence
(without medication overuse) as 0.066 % according to
ICHD-II criteria and the rate of CM was 0.56 % in new
incident patients diagnosed with definite migraine. To
our knowledge, this is the first population based study
presenting data on the incidence of CM. Furthermore,
female sex is reported as a risk factor for CM in a recent
study [34].
ICHD criteria specifically exclude MOH from the CM
definition. A large prospective study from Norway re-
ported that the MOH incidence was 0.72 per 1000
persons-years [35], which was higher than the incidence
rate found in the current study. There is evidence for an
association between the chronicity of headache and
medication overuse [36, 37], but the causal relationship
remains uncertain. Nearly one third of our patients with
chronic headache did not have medication overuse simi-
lar to previous reports [38] which may suggest that the
genetic factors might play a role in the development of
headache chronification. The transition to CM may also
Fig. 2 Consulted type of physician for headache and with definite migraine in 2008 and in 2013
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be influenced by environmental factors such as lifestyle,
awareness, education, detrimental life events, comorbid
conditions besides personal genetic pattern [39]. On the
other hand, Lipton et al. reported that inadequate treat-
ment was a risk factor for new onset CM [40] and found
that the greatest barrier for an appropriate treatment oc-
curred at the level of consulting a health care profes-
sional [41]. Our findings revealed that 50–70 % of
patients consulted a physician for headache but the new
incident cases consulted more often an internal medi-
cine specialist than a neurologist in our country. Thus, it
seems that headache patients are less likely seen by a
neurologist in the early years of their disease and this
could also have an impact on the high CM incidence. In-
creasing awareness about the need for consultation by a
neurologist, specifically trained for headache may help
to prevent chronification of migraine.
The burden of migraineurs
The individual impact of migraine related to the duration,
severity and frequency of the attack is well-known, but the
changes during years are not well investigated. However,
migraine may also have cumulative impact over time.
Many studies in the United Kingdom and the United
States reported substantial impact and burden of migraine
on family life, social relationships, like postponing their
household work (85 %) canceling family and social activ-
ities (45 %) etc. [42–45]. Our study is unique to report the
burden of headache particularly in new-onset migraineurs
and confirmed that migraine can lead to disruption of
work, family and social life and affect quality of life, even
in the early stages of the disease.
Speculations on predictors of migraine onset
Despite clear evidence of genetic contribution to migraine
onset, modifying or triggering effects of some environ-
mental factors such as education level, socio-economic
status, and premorbid depression are also debated in the
relevant reports.
a) A higher prevalence of migraine was observed in
clinical series of individuals having a higher level of
education in some studies, whereas some other
studies reported just the opposite [3, 46, 47] . Our
current study did not show any effect of education
on the migraine onset in migraine-free individuals,
whereas in the same population, we had previously
found lower migraine prevalence in those with a
lower educational status than those with a high
educational status [14].
b) Some population-based studies have found that
migraine prevalence is inversely related to income
in the US [46, 48, 49]. On the other hand, no
such correlation was found in studies conducted
in Europe [50–53], nor in two other studies from
North America [43, 54], similar to our results.
However, in a recent study we showed that
migraine prevalence was higher (26.4 %) among
women with a lower income (less than 1,300 US$
monthly) than the ones with a higher income
(20.3 %), while in men, it was the same in the
ones with lower income (8.5 %) and the ones with
higher income (8.5 %) [14].
c) Many studies already pointed out that family history
of migraine is especially important in migraine
prediction and persistence [55, 56]. Our results
showed that history of headache in the father is a
more important predictor for new-onset cases for
migraine. It could be wisely speculated that headache
history in the mother is very frequent in the general
population and therefore, the genetic tendency from
paternal side may be more important for the migraine
onset.
d) Association of migraine with depression has also
been well established in population based studies
besides clinical samples [21, 57]. Our study supplied
evidence that migraine-free individuals who received
physician diagnosis and treatment for depression
have significantly increased rates of new incident
migraine when compared to those without depression
history. Taken together with the increased family
history, it is reasonable to conclude that this
comorbidity may be based on a shared genetic
background [58, 59].
Weaknesses and strengths of our study
The current gold standard of headache diagnosis is per-
sonal interview and examination by an experienced
physician; thus our initial study has fulfilled this stand-
ard. However, this is a rather expensive approach and
in the second part of the incidence study we applied
telephone interviews by trained staff according to
ICHD-II criteria, which was reported to be acceptable
for screening purposes [3]. Furthermore, this telephone
questionnaire has been meticulously validated two
times taking the expert diagnosis as the gold standard,
which increased the reliability of our results. There are
relatively few studies using validation of their methods
in a sample after interview and examination by a neur-
ologist or headache expert. [3, 60, 61] We have a mod-
erate participation rate of 56.4 % for the telephone
survey which could represent a potential selection bias.
This rate is indeed not very low when the 5 years interval
was taken into account and when compared to other simi-
lar studies. But subjects with headache (and even more
subjects with a recent-onset headache) might be eager to
participate in the headache interview when compared
to headache-free individuals. Moreover it should be
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emphasized that our study underestimated migraine
incidence in the 18–24 age group, since the original
population in 2008 was aged over 18 years.
It has been well-known that there is overlap in symp-
tomatology between headache subtypes and multiple
headache types often coexist in the same individual; for
example great majority of migraineurs also have tension
type headache (TTH) creating diagnostic confusion for
many studies [7]. Therefore we only investigated the
migraine incidence to obtain rather solid results and
mainly focused on patients strictly diagnosed with mi-
graine according to the ICHD-II, which is currently
most elaborate and comprehensive system for classify-
ing migraine.
The strengths of our study were the representative
sampling of a population-based nation-wide study ac-
complished by trained physicians, use of ICHD-II cri-
teria, and the structured headache interviews, blinded
re-evaluation of the previous diagnoses. The validity
and reliability of telephone interviews were found to
have very good agreement with the clinical interviews
in studies assessing the telephone interviews by com-
parison with the “gold standard” which was accepted
as clinical interviews by experts [60].
Conclusions
Our study showed a 2.38 % incidence rate of migraine in
Turkey, higher than most of the other previous reports;
a finding which could be related to genetic factors and
also to the methodological differences in the study de-
signs. Moreover, the incidence of CM was found to be
0.066 % and that of MOH was 0.259 %.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
BB participated in the design of the study, analysis of the data and wrote the
draft of the manuscript together with EE. ME participated in the design of
the study, analyzed the data and performed the statistical analysis besides
helping the revisions. NK participated in the design of the study and have
made substantial contributions to the acquisition of data and also revised
the manuscript critically for important intellectual content. DU and UU have
made substantial contributions to the acquisition of data namely for the
validation part. EKO involved in the design of the study particularly the first
questionnaire part and has made substantial contributions to the acquisition
of data. SS, MZ and AS participated in the design of the study and have
been involved in revising the manuscript critically for important intellectual
content. All authors have given final approval of the current version to be
published.
Acknowledgement
This study was supported by an unrestricted research grant of Ibrahim
Ethem Ulagay-Menarini Group. The authors thank Rana Sengil and Isil Celik
Uzuncakmak from I.E. Ulagay - Menarini Group for their special efforts in
coordination.
Author details
1Department of Neurology, Istanbul Faculty of Medicine, Istanbul University,
Millet Cad, 34390 Capa/Istanbul, Turkey. 2Department of Neurology, School
of Medicine, University of Uludag, Bursa, Turkey. 3Department of Neurology,
Cerrahpasa School of Medicine, Istanbul University, Millet Cad, 34390 Capa/
Istanbul, Turkey.
Received: 7 September 2015 Accepted: 30 November 2015
References
1. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P
(2015) Headache disorders are third cause of disability worldwide.
J Headache Pain 16:58
2. WHO, Lifting the burden (2011) Atlas of headache disorders and resources
in the world 2011. http://www.who.int/mental_health/management/atlas_
headache_disorders/en/
3. Manzoni GC, Stovner LJ (2011) Epidemiology of headache. In: Nappi G,
Moskowitz MA (eds) Headache Handbook of Clinical Neurology vol. 97,3rd
series. Elsevier, Edinburgh, pp 3–22
4. Bigal ME, Lipton RB (2009) The epidemiology, burden, and comorbidities of
migraine. Neurol Clin 27(2):321–334
5. Khil L, Pfaffenrath V, Straube A, Evers S, Berger K (2012) Incidence of
migraine and tension-type headache in three different populations at risk
within the German DMKG headache study. Cephalalgia 32(4):328–336
6. Headache Classification Subcommittee of the International Headache
Society (2004) The international classification of headache disorders: 2nd
edn. Cephalalgia 24:9–160
7. Merikangas KR (2013) Contributions of epidemiology to our understanding
of migraine. Headache 53(2):230–246
8. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM (2003) Comorbidity
of migraine and depression: investigating potential etiology and prognosis.
Neurology 60(8):1308–1312
9. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R (2005) Incidence of
primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol
161(11):1066–1073
10. Nachit-Ouinekh F, Dartigues JF, Chrysostome V, Henry P, Sourgen C, El
Hasnaoui A (2005) Evolution of migraine after a 10-year follow-up.
Headache 45(10):1280–1287
11. Camarda R, Monastero R, Santangelo G, Raimondo D, Puma D, Pipia C,
Camarda LK, Camarda C, Raieli V (2002) Migraine headaches in adolescents:
a five-year follow-up study. Headache 42(10):1000–1005
12. Bille B (1997) A 40-year follow-up of school children with migraine.
Cephalalgia 17(4):488–491, discussion 487
13. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB (2008) Cumulative lifetime
migraine incidence in women and men. Cephalalgia 28(11):1170–1178
14. Ertas M, Baykan B, Orhan EK, Zarifoglu M, Karli N, Saip S, Onal AE, Siva A
(2012) One-year prevalence and the impact of migraine and tension-type
headache in Turkey: a nationwide home-based study in adults. J Headache
Pain 13(2):147–157
15. Rasmussen BK (1995) Epidemiology of headache. Cephalalgia 15(1):45–68
16. Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D (1991)
Age- and sex-specific incidence rates of migraine with and without
visual aura. Am J Epidemiol 134(10):1111–1120
17. Stang PE, Yanagihara PA, Swanson JW, Beard CM, O'Fallon WM, Guess HA,
Melton LJ 3rd (1992) Incidence of migraine headache: a population-based
study in Olmsted County, Minnesota. Neurology 42(9):1657–1662
18. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR (2008)
Migraine incidence, comorbidity and health resource utilization in the UK.
Cephalalgia 28(1):57–64
19. Breslau N, Davis GC, Schultz LR, Peterson EL (1994) Joint 1994 Wolff Award
Presentation, Migraine and major depression: a longitudinal study.
Headache 34(7):387–393
20. Breslau N, Chilcoat HD, Andreski P (1996) Further evidence on the link
between migraine and neuroticism. Neurology 47(3):663–667
21. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW (2000) Mental
disorders and the incidence of migraine headaches in a community sample:
results from the Baltimore Epidemiologic Catchment area follow-up study.
Arch Gen Psychiatry 57(10):945–950
22. Baykan B, Ertas M, Karli N, Akat-Aktas S, Uzunkaya O, Zarifoglu M, Siva A,
Saip S, MIRA-Neurology Study Group (2007) The burden of headache in
neurology outpatient clinics in Turkey. Pain Pract 7(4):313–323
23. Zarifoglu M, Siva A, Hayran O, Group THES (1998) An epidemiological study
of headache in Turkey: a nationwidesurvey. Neurology 50:A225
Baykan et al. The Journal of Headache and Pain  (2015) 16:103 Page 9 of 10
24. Silva Junior AA, Bigal M, Vasconcelos LP, Rodrigues J, Gomez RS,
Krymchantowski AV, Moreira Filho P, Teixeira AL (2012) Prevalence and
burden of headaches as assessed by the health family program. Headache
52(3):483–490
25. Ferrante T, Castellini P, Abrignani G, Latte L, Russo M, Camarda C, Veronesi
L, Pasquarella C, Manzoni GC, Torelli P (2012) The PACE study: past-year
prevalence of migraine in Parma's adult general population. Cephalalgia
32(5):358–365
26. Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and
disease burden. Curr Pain Headache Rep 15(1):70–78
27. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010)
Global prevalence of chronic migraine: a systematic review. Cephalalgia
30(5):599–609
28. Evans RW (2013) A rational approach to the management of chronic
migraine. Headache 53(1):168–176
29. Schramm SH, Obermann M, Katsarava Z, Diener HC, Moebus S, Yoon MS
(2013) Epidemiological profiles of patients with chronic migraine and
chronic tension-type headache. J Headache Pain 14:40
30. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB
(2012) Chronic migraine prevalence, disability, and sociodemographic
factors: results from the American Migraine Prevalence and Prevention
Study. Headache 52(10):1456–1470
31. Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze
M, Jensen R, Stovner LJ, Steiner TJ (2009) Primary headache disorders in
the Republic of Georgia: prevalence and risk factors. Neurology 73(21):
1796–1803
32. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute
migraine medications and evolution from episodic to chronic migraine: a
longitudinal population-based study. Headache 48(8):1157–1168
33. Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and
near-daily headaches: field trial of revised IHS criteria. Neurology 47(4):
871–875
34. Carod-Artal FJ (2014) Tackling chronic migraine: current perspectives. J Pain
Res 7:185–194
35. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA (2012) Risk factors for
medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag
Health Studies. Pain 153(1):56–61
36. Castillo J, Munoz P, Guitera V, Pascual J (1999) Kaplan Award 1998,
Epidemiology of chronic daily headache in the general population.
Headache 39(3):190–196
37. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ (2001) Chronic daily headache
in Taipei, Taiwan: prevalence, follow-up and outcome predictors.
Cephalalgia 21(10):980–986
38. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A,
Diener HC, Limmroth V (2004) Incidence and predictors for chronicity of
headache in patients with episodic migraine. Neurology 62(5):788–790
39. Negro A, Martelletti P (2011) Chronic migraine plus medication overuse
headache: two entities or not? J Headache Pain 12(6):593–601
40. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015)
Ineffective acute treatment of episodic migraine is associated with
new-onset chronic migraine. Neurology 84(7):688–695
41. Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC (2013)
Barriers to the diagnosis and treatment of migraine: effects of sex, income,
and headache features. Headache 53(1):81–92
42. Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003)
The family impact of migraine: population-based studies in the USA and UK.
Cephalalgia 23(6):429–440
43. Kryst S, Scherl E (1994) A population-based survey of the social and
personal impact of headache. Headache 34(6):344–350
44. Smith R (1998) Impact of migraine on the family. Headache 38(6):423–426
45. Holmes WF, MacGregor EA, Dodick D (2001) Migraine-related disability:
impact and implications for sufferers' lives and clinical issues. Neurology
56(6 Suppl 1):13–19
46. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of
migraine headache in the United States. Relation to age, income, race, and
other sociodemographic factors. JAMA 267(1):64–69
47. Stang P, Sternfeld B, Sidney S (1996) Migraine headache in a prepaid health
plan: ascertainment, demographics, physiological, and behavioral factors.
Headache 36:69–76
48. Lipton RB, Stewart WF, Scher AI (2001) Epidemiology and economic impact
of migraine. Curr Med Res Opin 17(Suppl 1):4–12
49. Lipton RB, Bigal ME (2005) Migraine: epidemiology, impact, and risk factors
for progression. Headache 45(Suppl 1):3–13
50. Rasmussen BK (1992) Migraine and tension-type headache in a general
population: psychosocial factors. Int J Epidemiol 21(6):1138–1143
51. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and
characteristics of migraine in a population-based cohort: the GEM study.
Neurology 53(3):537–542
52. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003)
The prevalence and disability burden of adult migraine in England and their
relationships to age, gender and ethnicity. Cephalalgia 23(7):519–527
53. Koehler T, Buck-Emden E, Dulz K (1992) Frequency of of employees and
variation of prevalence according to different diagnostic criteria. Headache
32(2):79–83
54. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF (2002)
Migraine in the United States: epidemiology and patterns of health care
use. Neurology 58(6):885–894
55. Monastero R, Camarda C, Pipia C, Camarda R (2006) Prognosis of
migraine headaches in adolescents: a 10-year follow-up study.
Neurology 67(8):1353–1356
56. Ducros A, Tournier-Lasserve E, Bousser MG (2002) The genetics of migraine.
Lancet Neurol 1(5):285–293
57. Breslau N, Davis GC (1992) Migraine and psychiatric disorders: a prospective
epidemiologic study. Clin Neuropharmacol 15 Suppl 1 Pt A:279A–280A
58. Breslau N, Davis GC (1992) Migraine, major depression and panic disorder: a
prospective epidemiologic study of young adults. Cephalalgia 12(2):85–90
59. Ligthart L, Nyholt DR, Penninx BW, Boomsma DI (2010) The shared genetics
of migraine and anxious depression. Headache 50(10):1549–1560
60. Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G (2000) Head-HUNT: validity
and reliability of a headache questionnaire in a large population-based
study in Norway. Cephalalgia 20(4):244–251
61. Laurell K, Larsson B, Eeg-Olofsson O (2004) Prevalence of headache in
Swedish schoolchildren, with a focus on tension-type headache.
Cephalalgia 24(5):380–388
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Baykan et al. The Journal of Headache and Pain  (2015) 16:103 Page 10 of 10
